Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.

This study found that nonobese women with idiopathic hirsutism had significantly lower nitrite/nitrate concentrations and higher fibrinogen levels compared to controls, but similar levels to women with PCOS.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.

This review discusses the clinical use of anti-androgen medications and highlights emerging evidence supporting plant-derived anti-androgens like spearmint tea for managing PCOS, but reports no new clinical results.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This review discusses the natural progression of androgenetic alopecia and potential factors influencing its long-term prognosis, reporting no new clinical results.

This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.

This study identified enzymes responsible for regulating androgen action in the human prostate, suggesting that inhibiting AKR1C2 or RL-HSD may have therapeutic potential in androgen insufficiency or benign prostatic hyperplasia, respectively.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This review discusses the structure and function of steroid nuclear receptors, particularly focusing on androgen receptor dysregulation in prostate cancer and androgen insensitivity syndromes, without reporting new experimental results.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

In this study, the authors observed that testosterone therapy shortened the QTc interval and normalized T-wave morphology in men with acquired LQTS or TdP linked to hypogonadism, suggesting testosterone may be helpful in treatment.

This review discusses the potential severe consequences of androgenic alopecia, including its association with psychosocial distress and an increased risk for certain diseases, and highlights the need for comprehensive medical evaluation.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This review discusses the clinical aspects, diagnosis, and treatment options for androgenetic alopecia, ultimately calling for further research, particularly regarding older populations and possible health risks.

This article reviews the association between androgenic alopecia and metabolic syndrome, highlighting the importance of early diagnosis and lifestyle changes to manage associated health risks, but reports no new clinical results.

This study used machine learning to develop classifiers for identifying effective inhibitors of 5α-reductase isozyme 2, achieving high performance in distinguishing potent from weak inhibitors.

Hair loss can be an early sign of prostate enlargement.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This review discusses the use of antiandrogens for various conditions like prostate cancer and highlights their potential benefits in remission rates and symptom improvement, but it reports no new clinical results.

This review discusses androgen and antiandrogen studies in COVID-19, noting potential impacts on disease severity and suggesting the need for more data on their effectiveness and safety.

This study characterized the SARM PF-05314882, finding it demonstrates anabolic activity in rats with minimal effects on the prostate, seminal vesicles, and luteinizing hormone levels.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This article discusses the structure of the human type II 5 alpha-reductase gene and reports no new experimental results.

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.